AltaRex Receives Notice of Issuance of Patent from European Patent Office.Business Editors/Health/Medical Writers EDMONTON, Alberta--(BUSINESS WIRE)--Oct. 6, 2003 AltaRex Corp. (OTC OTC See: Over-the-counter. OTC See over-the-counter market (OTC). Pink Sheets:ALXFF)(TSE See Tokyo Stock Exchange. TSE 1. See Tokyo Stock Exchange (TSE). 2. See Toronto Stock Exchange (TSE). :AXO AXO Asianxo (website) AXO Alpha Chi Omega (sorority) AXO Ach So AXO Access Extension Object ), ("AltaRex" or the "Company"), announced today that it has been granted a "multi-epitopic" patent from the European Patent Office (EPO EPO see erythropoietin. EPO Erythropoietin, see there ) applicable to the Company's lead product OvaRex(R) MAb (oregovomab). The "multi-epitopic" patent is a cornerstone of the Company's intellectual property holdings, and corresponds to a previously issued patent (effective June 5, 2001) by the U.S. Patent and Trademark Office. With the EPO's grant of the "multi-epitopic" patent for the European Union (EU), the Company is now able to protect OvaRex(R) in the great majority of worldwide markets. OvaRex(R) is the Company's most advanced product in a phase III clinical trial Noun 1. phase III clinical trial - a large clinical trial of a treatment or drug that in phase I and phase II has been shown to be efficacious with tolerable side effects; after successful conclusion of these clinical trials it will receive formal approval from the for the treatment of advanced ovarian cancer. The "multi-epitopic" patent covers the Company's novel technology of administering (intravenously) a low-dose foreign antibody (OvaRex(R) MAb) to any patient expressing the target tumor-antigen (CA125). AltaRex's antibodies are designed to trigger multiple immune responses (multi-epitopic) against the tumor itself and its metastatic components in the body. This specific anti-tumor effect results in a clinical response beneficial to the cancer patient. Dr. Antoine Noujaim, President and CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board. of AltaRex commented, "The issuance of this patent is an important step in strengthening our position in the development of OvaRex(R) and our other antibodies in the European market." AltaRex is focused on the research, development and commercialization of foreign antibodies that modulate the immune system for the treatment of certain cancers and other diseases where there exists an unmet medical need. Additional information about AltaRex research and development, clinical trials, news and events can be found on the Company website www.altarex.com. The Toronto Stock Exchange Toronto Stock Exchange (TSE) Canada's largest stock exchange, trading approximately 1,200 company stocks and 33 options. has not approved or disapproved of the information contained herein. |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion